利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.019 秒)

    Directly compressible formulations of azithromycin
    1.
    发明授权
    Directly compressible formulations of azithromycin 失效

    公开(公告)号：US07070811B2

    公开(公告)日：2006-07-04

    申请号：US11190393

    申请日：2005-07-26

    申请人： Brendan Murphy ,  Steven W. Collier ,  Ernest Quan ,  Barbara A. Johnson

    发明人： Brendan Murphy ,  Steven W. Collier ,  Ernest Quan ,  Barbara A. Johnson

    IPC分类号： A61K9/14 ,  A61K31/70

    CPC分类号： A61K31/7052 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2095

    摘要： The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient.This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet.Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin.This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

    Pharmaceutical compositions of atorvastatin
    2.
    发明授权
    Pharmaceutical compositions of atorvastatin 失效
    阿托伐他汀的药物组合物

    公开(公告)号：US07790197B2

    公开(公告)日：2010-09-07

    申请号：US10828079

    申请日：2004-04-20

    申请人： Michael B. Fergione ,  Barbara A. Johnson ,  Kenneth Craig Waterman

    发明人： Michael B. Fergione ,  Barbara A. Johnson ,  Kenneth Craig Waterman

    IPC分类号： A61K9/26

    CPC分类号： A61K9/1623 ,  A61K9/1652 ,  A61K31/40

    摘要： A wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof with less than about 5 weight % of an alkaline earth metal salt additive with a disintegrant which provides the atorvastatin with not more than about 3% atorvastatin lactone based on the ratio of lactone peak area compared to the total drug-related peak integrated areas, as well as said wet granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical compositions.

    摘要翻译： 一种湿颗粒状药物组合物，其包含阿托伐他汀或其药学上可接受的盐和小于约5重量％的具有崩解剂的碱土金属盐添加剂，其基于内酯峰的比例提供阿托伐他汀不超过约3％的阿托伐他汀内酯 以及所述含有阿托伐他汀或其药学上可接受的盐与至少一种其它活性药物组合的湿法制粒药物组合物，所述组合物的制备方法，用于含有该组合物的试剂盒， 以及使用治疗有效量的药物组合物治疗高胆固醇血症和/或高脂血症，骨质疏松症，良性前列腺增生症（BPH）和阿尔茨海默病的方法。

    STABLE NON-DIHYDRATE AZITHROMYCIN ORAL SUSPENSIONS
    3.
    发明申请
    STABLE NON-DIHYDRATE AZITHROMYCIN ORAL SUSPENSIONS 审中-公开
    稳定的非二异丙基纤维素口服悬浮液

    公开(公告)号：US20100048498A1

    公开(公告)日：2010-02-25

    申请号：US11722279

    申请日：2005-12-09

    申请人： Barbara A. Johnson ,  Brendan J. Murphy

    发明人： Barbara A. Johnson ,  Brendan J. Murphy

    IPC分类号： A61K31/7052 ,  A61P31/00

    CPC分类号： A61K9/0095 ,  A61K31/7048 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00

    摘要： This invention relates to a powder for oral suspension, and an oral suspension made there from, which comprises non-dihydrate azithromycin and an azithromycin conversion stabilizing excipient, wherein said excipient reduces the conversion of the form of azithromycin, when placed in suspension, to another form of azithromycin.This invention further relates to a method for reducing the conversion of a form of non-dihydrate azithromycin, in an oral suspension, by including at least one cyclodextrin in said oral suspension.

    摘要翻译： 本发明涉及用于口服悬浮液的粉末和由其制备的口服悬浮液，其包含非二水合阿奇霉素和阿奇霉素转化稳定赋形剂，其中所述赋形剂将阿奇霉素的形式在悬浮液中降低至另一种 阿奇霉素的形式。 本发明还涉及通过在所述口服悬浮液中包含至少一种环糊精来减少口服悬浮液中的一种形式的二水合阿奇霉素的转化的方法。

    Fly swatter device
    5.
    发明授权
    Fly swatter device 失效
    飞溅装置

    公开(公告)号：US4910909A

    公开(公告)日：1990-03-27

    申请号：US381463

    申请日：1989-07-18

    申请人： Michael R. Johnson ,  Barbara A. Johnson

    发明人： Michael R. Johnson ,  Barbara A. Johnson

    IPC分类号： A01M3/02

    CPC分类号： A01M3/02

    摘要： A fly swatter device is set forth wherein housing formed with an open upper end telescopingly receives a slide member interiorly thereof. The slide member is latched in a lower first position and extended to a second telescoping position. An array of striker slats is pivotally mounted to an axle orthogonally directed through opposed walls of the slide member utilizing an elastomeric cord to expand the slats to a splayed orientation upon the slide member extending to the second position.

    摘要翻译： 提出了一种飞溅装置，其中形成有敞开的上端的壳体在其内部可伸缩地容纳滑动构件。 滑动构件被锁定在较低的第一位置并且延伸到第二伸缩位置。 撞击板条的一组阵列利用弹性体帘线枢转地安装到通过滑动构件的相对壁正交地引导的车轴，以在滑动构件延伸到第二位置时将板条扩展到展开方向。

    Dry granulated formulations of azithromycin
    6.
    发明授权
    Dry granulated formulations of azithromycin 失效
    阿奇霉素干颗粒制剂

    公开(公告)号：US07438924B2

    公开(公告)日：2008-10-21

    申请号：US10355575

    申请日：2003-01-31

    申请人： Barbara A. Johnson ,  Ernest S. Quan

    发明人： Barbara A. Johnson ,  Ernest S. Quan

    IPC分类号： A01N25/34 ,  A61K31/70

    CPC分类号： A61K31/70 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2095

    摘要： This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin.More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof.Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA.The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.

    摘要翻译： 本发明涉及一种片剂形式的药物制剂，用于悬浮剂型的小药囊或粉剂，其包含非二水合形式的阿奇霉素和任选的一种或多种药学上可接受的赋形剂的干燥造粒颗粒。 优选地，药物制剂是含有约40重量％至约90重量％的非二水合阿奇霉素的片剂。 更优选地，药物制剂含有选自形式B，D，E，F，G，H，J，M，N，O，P，Q，R或其混合物的非二水合阿奇霉素。 更优选地，本发明涉及药物制剂，其中阿奇霉素的剂量为250mgA，500mgA，600mgA或1000mgA。 本发明还涉及一种包含形式D，E，F，G，H，J，M，N，O，P，Q，R和非二水合物混合物的阿奇霉素形式的干燥粒状阿奇霉素颗粒 形式和至少一种药学上可接受的赋形剂。